肯尼亚发现第二例全药耐药Candidozyma auris
Second-ever case of rare fungus resistant to four antifungal drug classes detected in Kenya
肯尼亚28岁患者分离出第二例全球记录的全药耐药Candidozyma auris,该菌株对四类抗真菌药物均耐药。全基因组测序显示其属于南亚谱系,特定基因突变解释了耐药性,但多烯类耐药机制尚不明确。
案例提供了全耐药真菌的基因组学证据,为资源有限地区制定防控方案提供直接参考。
While a mutant fungus in the real world might not be making humans violent and turning them against each other as in the fictional world of "The Last of Us," it is raising alarm bells for public health.
Candidozyma auris is a yeast that can cause invasive infections and has been flagged in World Health Organization lists as a top-priority threat, as it spreads easily in hospitals. This notorious fungus survives for long periods on surfaces and often resists major classes of antifungal medications used to treat fungal infections.
A recent study uncovered an extremely rare fungal strain that can withstand all four major classes of antifungal drugs—azoles, echinocandins, polyenes and flucytosine.
Researchers isolated the pan-drug-resistant strain from a 28-year-old patient who developed a surgical wound infection while hospitalized in Nairobi, Kenya. This is the first time a pan-drug-resistant strain of the fungus has been identified in Africa and only the second documented case worldwide. The first case was reported in New York.
Genetic testing traced the fungus to a lineage already circulating in Kenya and identified a specific combination of drug-resistance mutations that could explain why the antifungal medicines failed.
The findings are published in Scientific Reports.
Dangerous traveling yeasts
Ever since its first isolation in Japan in 2009, Candidozyma auris has been globetrotting to over 60 countries across six continents, with 10,000 cases being reported in the U.S. alone. Unlike other Candida species, C. auris spreads easily in hospitals, causing outbreaks and serious invasive infections with 30%–50% mortality in some patient groups.
Most C. auris infections worldwide are multidrug-resistant, with over 90% of cases resisting azoles such as fluconazole. However, they generally remain susceptible to other antifungal drugs, particularly echinocandins. Even extensively drug-resistant strains resist three classes of antifungals, leaving doctors with at least one treatment option.
The fungal isolates in this case were pan-resistant, meaning they were resistant to all four classes of antifungals, with no standard treatment options for doctors to rely on.
Genes unlock resistance clues
To better understand the identity and inner workings of the rare strain, the researchers performed whole-genome sequencing, which revealed that the fungus belongs to Clade I, the South Asian lineage. The genetic analysis also linked specific DNA mutations to resistance against certain drugs.
Mutations in the ERG11 and CDR1 genes help the fungus resist azoles, while changes in FKS1 allow it to withstand echinocandins. Mutations in FUR1 and FCY1 also help it evade flucytosine.
Genetic analysis couldn't explain polyene resistance, but the team suggests altered levels of ergosterol, a molecule belonging to the steroid family that helps with cell membrane maintenance, or the formation of protective biofilms as potential driving factors.
The only other documented case of pan-drug-resistant C. auris was reported in New York, where the fungus developed resistance over the course of a prolonged hospital stay. The Kenyan strain, however, carries a different pattern of genetic mutations from its U.S. counterpart. The researchers thus believe that it evolved drug resistance independently rather than spreading from the United States.
The discovery of this case brings with it a warning that antimicrobial resistance is entering even more dangerous territory worldwide. The threat is particularly worrying for hospitals across Africa and other resource-limited regions, where newer, alternative antifungal medications are not widely available.
Written for you by our author Sanjukta Mondal, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.
Publication details
Erick Odoyo et al., Emergence of pan-drug resistant Candidozyma auris in Kenya, the second globally documented case, Scientific Reports (2026). DOI: 10.1038/s41598-026-70653-9
Journal information: Scientific Reports
Key medical concepts
Who's behind this story?
Sanjukta Mondal
Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
© 2026 Science X Network
Citation: Second-ever case of rare fungus resistant to four antifungal drug classes detected in Kenya (2026, October 19) retrieved 19 October 2026 from https://medicalxpress.com/news/2026-10-case-rare-fungus-resistant-antifungal.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com